Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice

Clinical and Experimental Rheumatology

Alan Davis¹  Bruce Freundlich¹  Robert J. Moots¹  David J Chang¹  Boulos Haraoui¹  Thierry Schaeverbeke¹  Michael A. Tedeschi¹  Jörn Kekow¹  Marco Matucci-Cerinic¹  Amitabh Singh¹  Piet L.C.M. van Riel¹ 

关键词: Rheumatoid arthritis;    TNFα inhibitor;    dose escalation;    etanercept;    infliximab;    adalimumab;   

DOI  :  

学科分类：医学（综合）

来源: Pacini Editore SpA

【 摘 要 】

OBJECTIVES: To evaluate prevalence of dose escalation among RA patients in normal clinical practice treated with etanercept, adalimumab or infliximab and to estimate its economic impact. METHODS: A retrospective observational study of 739 patients with RA receiving continuous treatment with etanercept (n=319), adalimumab (n=313) or infliximab (n=107) for 18 months. Dose escalation, intensification of concomitant DMARDs and risk of dose escalation were evaluated, as well as costs. RESULTS: Significantly more patients prescribed adalimumab (10%, p

【 授权许可】

Unknown